Inhibition of BAMBI reduces the viability and motility of colon cancer via activating TGF‑β/Smad pathway in vitro and in vivo Retraction in /10.3892/ol.2021.12505

Yu,Wenzhen; Chai,Hong

doi:10.3892/ol.2017.6811

Inhibition of BAMBI reduces the viability and motility of colon cancer via activating TGF‑β/Smad pathway in vitro and in vivo

Retraction in: /10.3892/ol.2021.12505

Authors:
- Wenzhen Yu
- Hong Chai
View Affiliations

Affiliations: Department of Gastroenterology, The People's Hospital of Wuhan University, Wuchang, Wuhan, Hubei 430060, P.R. China
Published online on: August 24, 2017 https://doi.org/10.3892/ol.2017.6811
Pages: 4793-4799
Copyright: © Yu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colon cancer is a highly metastatic gastrointestinal cancer. BMP activin membrane‑bound inhibitor (BAMBI), as a pseudo‑receptor of the tumor growth factor (TGF)‑β signal transduction pathway, has previously been demonstrated to be involved in human cancers. The present study demonstrated that BAMBI‑small interfering (si)RNA regulated the viability and motility of colon cancer by activating TGF‑β signaling. The expression level of BAMBI was suppressed by transfecting BAMBI‑siRNA into the SW480 and HT‑29 colon cancer cell lines. Decreased cell proliferation and increased cell apoptosis were detected in SW480 and HT‑29 cells transfected with BAMBI‑siRNA. Decreased expression of proliferation marker proteins Ki67 and proliferating cell nuclear antigen and elevated expression of apoptosis marker proteins (caspases‑3, ‑8 and ‑9) further verified the role of BAMBI‑siRNA in inhibiting cell viability. Silencing of BAMBI strongly reduced the closing rate and the number of invasive cells compared with control group. BAMBI‑siRNA additionally resulted in decreased expression of migration marker proteins matrix metalloproteinase‑9 (MMP‑9), MMP‑14 and vascular endothelial cell growth factor. In addition, the expression of TGF‑β and phosphorylated‑mothers against decapentaplegic homolog (Smad) 2/3 was increased in W480 and HT‑29 cells transfected with BAMBI‑siRNA. Elevated expression of the downstream signaling molecule E2F transcription factor 4/5 and suppressed c‑MYC were additionally detected in the BAMBI‑siRNA group. Finally, the in vivo experiment in the CSC xenograft revealed that BAMBI‑siRNA strongly reduced the tumor growth and tumor volume. BAMBI‑siRNA inhibited hepatic metastases and the expression of metastasis‑associated proteins. The upregulated expression of TGF‑β signaling proteins were detected in the BAMBI‑siRNA group compared with control group in vivo. Overall, the results of the present study indicated that the inhibition of BAMBI reduces the viability and motility of colon cancer and may involve activation of the TGF‑β/Smad pathway in vitro and in vivo.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
2	Pugh SA, Shinkins B, Fuller A, Mellor J, Mant D and Primrose JN: Site and stage of colorectal cancer influence the likelihood and distribution of disease recurrence and postrecurrence survival: Data from the FACS randomized controlled trial. Ann Surg. 263:1143–1147. 2016. View Article : Google Scholar : PubMed/NCBI
3	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI
4	Wolpin BM and Mayer RJ: Systemic treatment of colorectal cancer. Gastroenterology. 134:1296–1310. 2008. View Article : Google Scholar : PubMed/NCBI
5	Onichtchouk D, Chen YG, Dosch R, Gawantka V, Delius H, Massagué J and Niehrs C: Silencing of TGF-beta signalling by the pseudoreceptor BAMBI. Nature. 401:480–485. 1999. View Article : Google Scholar : PubMed/NCBI
6	Degen WG, Weterman MA, van Groningen JJ, Cornelissen IM, Lemmers JP, Agterbos MA, van Kessel Geurts A, Swart GW and Bloemers HP: Expression of nma, a novel gene, inversely correlates with the metastatic potential of human melanoma cell lines and xenografts. Int J Cancer. 65:460–465. 1996. View Article : Google Scholar : PubMed/NCBI
7	Sasaki T, Sasahira T, Shimura H, Ikeda S and Kuniyasu H: Effect of Nma on growth inhibition by TGF-betaa in human gastric carcinoma cell lines. Oncol Rep. 11:1219–1223. 2004.PubMed/NCBI
8	Sekiya T, Adachi S, Kohu K, Yamada T, Higuchi O, Furukawa Y, Nakamura Y, Nakamura T, Tashiro K, Kuhara S, et al: Identification of BMP and activin membrane-bound inhibitor (BAMBI), an inhibitor of transforming growth factor-beta signaling, as a target of the beta-catenin pathway in colorectal tumor cells. J Biol Chem. 279:6840–6846. 2004. View Article : Google Scholar : PubMed/NCBI
9	Oft M, Heider KH and Beug H: TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol. 8:1243–1252. 1998. View Article : Google Scholar : PubMed/NCBI
10	Hata A, Shi Y and Massagué J: TGF-beta signaling and cancer: Structural and functional consequences of mutations in Smads. Mol Med Today. 4:257–262. 1998. View Article : Google Scholar : PubMed/NCBI
11	Grady WM, Myeroff LL, Swinler SE, Rajput A, Thiagalingam S, Lutterbaugh JD, Neumann A, Brattain MG, Chang J, Kim SJ, et al: Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. Cancer Res. 59:320–324. 1999.PubMed/NCBI
12	Bierie B and Moses HL: Tumour microenvironment: TGFbeta: The molecular Jekyll and Hyde of cancer. Nat Rev Cancer. 6:506–520. 2006. View Article : Google Scholar : PubMed/NCBI
13	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
14	Subramaniam N, Sherman MH, Rao R, Wilson C, Coulter S, Atkins AR, Evans RM, Liddle C and Downes M: Metformin-mediated Bambi expression in hepatic stellate cells induces prosurvival Wnt/β-catenin signaling. Cancer Prev Res (Phila). 5:553–561. 2012. View Article : Google Scholar : PubMed/NCBI
15	Miao S, Zhao L, Gao J, Wang H and Cui Z: Distribution and mRNA Expression of BAMBI in Non-small-cell Lung Cancer. Zhongguo Fei Ai Za Zhi. 12:203–207. 2009.(In Chinese). PubMed/NCBI
16	Lin Z, Gao C, Ning Y, He X, Wu W and Chen YG: The pseudoreceptor BMP and activin membrane-bound inhibitor positively modulates Wnt/beta-catenin signaling. J Biol Chem. 283:33053–33058. 2008. View Article : Google Scholar : PubMed/NCBI
17	Zhang Y, Yu Z, Xiao Q, Sun X, Zhu Z, Zhang J, Xu H, Wei M and Sun M: Expression of BAMBI and its combination with Smad7 correlates with tumor invasion and poor prognosis in gastric cancer. Tumour Biol. 35:7047–7056. 2014. View Article : Google Scholar : PubMed/NCBI
18	Khin SS, Kitazawa R, Win N, Aye TT, Mori K, Kondo T and Kitazawa S: BAMBI gene is epigenetically silenced in subset of high-grade bladder cancer. Int J Cancer. 125:328–338. 2009. View Article : Google Scholar : PubMed/NCBI
19	Liu K, Song X, Ma H, Liu L, Wen X, Yu J, Wang L and Hu S: Knockdown of BAMBI inhibits β-catenin and transforming growth factor beta to suppress metastasis of gastric cancer cells. Mol Med Rep. 10:874–880. 2014. View Article : Google Scholar : PubMed/NCBI
20	Zhao JJ, Hao S, Wang LL, Hu CY, Zhang S, Guo LJ, Zhang G, Gao B, Jiang Y, Tian WG and Luo DL: Long non-coding RNA ANRIL promotes the invasion and metastasis of thyroid cancer cells through TGF-beta/Smad signaling pathway. Oncotarget. 7:57903–57918. 2016. View Article : Google Scholar : PubMed/NCBI
21	Rouce RH, Shaim H, Sekine T, Weber G, Ballard B, Ku S, Barese C, Murali V, Wu MF and Liu H: The TGF-β/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia. Leukemia. 30:800–811. 2016. View Article : Google Scholar : PubMed/NCBI
22	Jiang HL, Sun HF, Gao SP, Li LD, Hu X, Wu J and Jin W: Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-β/SMAD signaling. Oncotarget. 6:16352–16365. 2015. View Article : Google Scholar : PubMed/NCBI
23	Yu D, Shin HS, Lee YS and Lee YC: miR-106b modulates cancer stem cell characteristics through TGF-β/Smad signaling in CD44-positive gastric cancer cells. Lab Invest. 94:1370–1381. 2014. View Article : Google Scholar : PubMed/NCBI
24	Zhang B, Halder SK, Kashikar ND, Cho YJ, Datta A, Gorden DL and Datta PK: Antimetastatic role of Smad4 signaling in colorectal cancer. Gastroenterology. 138(969–980): e1–e3. 2010. View Article : Google Scholar
25	Togo N, Ohwada S, Sakurai S, Toya H, Sakamoto I, Yamada T, Nakano T, Muroya K, Takeyoshi I, Nakajima T, et al: Prognostic significance of BMP and activin membrane-bound inhibitor in colorectal cancer. World J Gastroenterol. 14:4880–4888. 2008. View Article : Google Scholar : PubMed/NCBI
26	Shangguan L, Ti X, Krause U, Hai B, Zhao Y, Yang Z and Liu F: Inhibition of TGF-β/Smad signaling by BAMBI blocks differentiation of human mesenchymal stem cells to carcinoma-associated fibroblasts and abolishes their protumor effects. Stem Cells. 30:2810–2819. 2012. View Article : Google Scholar : PubMed/NCBI
27	Lee S, Lee MJ, Zhang J, Yu GR and Kim DG: C-terminal-truncated HBV X promotes hepato-oncogenesis through inhibition of tumor-suppressive β-catenin/BAMBI signaling. Exp Mol Med. 48:e2752016. View Article : Google Scholar : PubMed/NCBI